




RealRate

PHARMACEUTICAL 2018

CNBX Pharmaceuticals Inc. Rank 130 of 342





RealRate

PHARMACEUTICAL 2018

CNBX Pharmaceuticals Inc. Rank 130 of 342



The relative strengths and weaknesses of CNBX Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CNBX Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 112% points. The greatest weakness of CNBX Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 29% points.

The company's Economic Capital Ratio, given in the ranking table, is 144%, being 98% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	3,517
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	699
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	287
Other Liabilities	0
Other Net Income	-74
Other Revenues	0
Property and Equipment	120
Research and Development	247
Selling, General and Administrative Expense	1,325

Output Variable	Value in 1000 USD
Assets	3,638
Liabilities	699
Expenses	1,860
Revenues	0
Stockholders Equity	2,939
Net Income	-1,934
Comprehensive Net Income	-1,934
Economic Capital Ratio	144%